Oculis Holding AG Ordinary shares - OCS STOCK NEWS

Oculis, a Swiss-based pharmaceutical company trading under the symbol OCS, has filed its Q2 Consolidated Financial Statements and Management's Discussion and Analysis (MD&A) with the SEC on Form 6-K. This follows an earlier press release announcing the same. The filings provide detailed financial information and management's perspective on the company's performance for the second quarter of 2024. Investors and analysts can now access these documents to gain deeper insights into Oculis's financial health, operational performance, and strategic direction.

Oculis Holding AG (Nasdaq: OCS; XICE: OCS) reported Q2 2024 financial results and provided company updates. Key highlights include:

1. Positive topline results from Phase 2b RELIEF trial of OCS-02 for Dry Eye Disease
2. Phase 2 ACUITY trial of OCS-05 for acute optic neuritis on track for Q4 2024 readout
3. Pre-NDA meeting with FDA completed for OCS-01 in post-operative inflammation and pain
4. Cash position of $131.2 million as of June 30, 2024, providing runway into 2H 2026
5. Q2 net loss of $23.0 million, compared to $14.3 million in Q2 2023
6. Raised $59 million in an oversubscribed registered direct offering

The company continues to advance its clinical programs, with strong momentum in DIAMOND-1 and DIAMOND-2 trials for DME.

Oculis Holding AG (Nasdaq: OCS; XICE: OCS) reported Q2 2024 financial results and provided a company update. Key highlights include:

1. Positive topline results from Phase 2b RELIEF trial of OCS-02 for Dry Eye Disease

2. Phase 2 ACUITY trial of OCS-05 for acute optic neuritis on track for Q4 2024 readout

3. Pre-NDA meeting completed for OCS-01 in post-operative inflammation and pain, with NDA submission planned for Q1 2025

4. Cash position of $131.2 million as of June 30, 2024, providing runway into 2H 2026

5. Q2 net loss of $23.0 million, primarily due to increased clinical development expenses

6. Continued progress in Phase 3 DIAMOND trials for OCS-01 in diabetic macular edema

Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company focused on eye care, has appointed Dr. Sharon Klier as Chief Development Officer. With over 20 years of experience in ophthalmology clinical development, Dr. Klier will oversee Oculis' ophthalmology pipeline. Her expertise spans early and late-stage programs, regulatory submissions, and approvals, particularly in retinal diseases, neuro-ophthalmology, and ocular inflammation.

Prior to joining Oculis, Dr. Klier served as Chief Development Officer, Head of Ophthalmology at UNITY Biotechnology. She has also held roles at Quark, Allergan, ISTA, and Pfizer. Oculis CEO Dr. Riad Sherif expressed confidence that Dr. Klier's expertise will be important in progressing the company's late-stage pipeline and executing its strategic vision.

Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical firm focused on eye care, announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference.

Riad Sherif, M.D., CEO of Oculis, will join a panel discussion titled 'Derisked Late-stage Candidates for Retinal Disorders' on August 15, 2024, at 11:00 am ET.

Additionally, Dr. Sherif will give a virtual company presentation available on-demand starting August 15, 2024, at 7:00 am ET.

Access to the presentation and panel discussion will be available through the Oculis website under the Events & Presentation page in the Investors & Media section.

Sabre Gold announced the results of its 2024 Annual General Meeting, held on May 29, 2024. Shareholders approved all agenda items and elected new board members, including Robert K. Warner and Arshad M. Khanani. Additionally, Baruch D. Kuppermann and Frank G. Holz were appointed to the Scientific Advisory Board. The company established a CHF 50 million flexible loan facility with BlackRock, providing significant financial flexibility, though no amounts were drawn at signing. The shareholders approved compensation packages for the Board and Executive Committee, including non-performance-related and variable compensations, as well as equity-based incentives. The company reported a loss of CHF 41.4 million for 2023, which will be carried forward. Key amendments to the articles of association were also approved, including the creation of conditional share capital for bonds and employee incentives.

Oculis Holding AG (Nasdaq: OCS) and EURETINA announced the establishment of the Ramin Tadayoni Award in memory of the late Chief Scientific Officer, Professor Ramin Tadayoni. The award, supported by Oculis, aims to recognize promising ophthalmologists in retina research. It includes €30,000 for research support and an additional €5,000 for the recipient. Applications will be accepted in June and July 2024, with the first award presented at the EURETINA Congress in September. This annual award honors Prof. Tadayoni's legacy and his significant contributions to ophthalmology.

Oculis has announced positive topline results from its Phase 2b RELIEF trial on licaminlimab, an anti-TNFα biologic eye drop for dry eye disease (DED). The trial showed significant improvements in multiple efficacy endpoints, particularly in patients with a TNFR1 genetic biomarker. Rapid treatment effects on corneal inflammation were noted by Day 15, with statistical significance by Day 43. Licaminlimab was well tolerated with no serious adverse events. Oculis plans to discuss these findings with the FDA and move into Phase 3 development. An investor and analyst webcast is scheduled for today at 8:30 am US Eastern Time.

Oculis has published notifications regarding transactions by its managerial staff. These transactions encompass annual equity incentive awards granted to company directors and one-time equity awards given to new directors upon their election to the board. The notifications cover the transactions of directors Ackermann, Khanani, Rosenberg, and Warner.